Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVSUH1)

Drug Name
JNJ-64565111 Drug Info
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Phase 2 [1]
Type-2 diabetes 5A11 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMVSUH1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Glucagon (GCG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PB-1023 DMZCI04 Type-2 diabetes 5A11 Phase 2 [2]
MK-8521 DMVNAYE Type-2 diabetes 5A11 Phase 2 [2]
MEDI0382 DMSV60C Type-2 diabetes 5A11 Phase 2 [2]
PT320 DMZYKXN Parkinson disease 8A00.0 Phase 2 [3]
SAR425899 DM53IPE Diabetic complication 5A2Y Phase 1 [2]
ZP2929 DMRVDUM Type-1 diabetes 5A10 Phase 1 [2]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon (GCG) TT0NUFM GLUC_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT03486392) A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. ACS Pharmacol Transl Sci. 2021 Mar 16;4(2):858-869.